Daewoong Pharmaceutical acquires cGMP approval of Nabota factory from US FDA
Daewoong Pharmaceutical(CEO Seung-Ho Jeon) received an establishment inspection report(EIR) which mentioned approval for the Nabota(prabotulinumtoxin A, DWP-450) manufacturing facility from the US Food and Drug Administration(FDA). Thus, Daewoong Pharmaceutical is now prepared to acquire approval...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.